Graft-vs-Host Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Type-1 regulatory T cells (Tr1 cells) and FoxP3<sup>+</sup> regulatory T cells (T<sub>regs</sub>) are predominant sources of IL-10 after SCT and the critical role of this cytokine in preventing GVHD is now established.
|
31640914 |
2019 |
Graft-vs-Host Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In vivo assays showed that the serologic IL-10 level was evidently lower in GVHD than in non-GVHD patients, whereas the IL-1β, IFN-γ, and tumor necrosis factor-α levels were higher in GVHD patients.
|
30142416 |
2019 |
Graft-vs-Host Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Rorc-/- T cells transplantation enhanced the frequency and function of intestinal ST2+ Tregs and reduced GVHD through decreased gut-infiltrating soluble ST2-producing type 1 and increased IL-4/IL-10-producing type 2 T cells.
|
30694220 |
2019 |
Graft-vs-Host Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
In Conclusions, our findings suggest that IL-10 gene-modified DC-induced Tr1 cells could inhibit GVHD while maintaining Graft-versus-leukemia (GVL) through mediating the shift of Th1/Th2 cytokines in an allo-BMT mice model.
|
30420284 |
2018 |
Graft-vs-Host Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
These findings provide for the first time a strong rationale for CD4<sup>IL-10</sup> cell immunotherapy to prevent GvHD and promote GvL in allo-HSCT for myeloid malignancies.
|
28807569 |
2017 |
Graft-vs-Host Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interleukin-10 Gene-Modified Dendritic Cell-Induced Type 1 Regulatory T Cells Induce Transplant-Tolerance and Impede Graft Versus Host Disease After Allogeneic Stem Cell Transplantation.
|
28869950 |
2017 |
Graft-vs-Host Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Although the potentiation of the GVT effect mediated by the CTC28 gene modification of T cells was accompanied by an increase of graft-versus-host disease (GVHD), the GVHD was not lethal and was mitigated by treatment with IL-10 gene-modified third-party mesenchymal stem cells.
|
28751785 |
2017 |
Graft-vs-Host Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
CD4(LV-IL-10) T cells were able to control xeno graft-versus-host disease (GvHD), demonstrating their suppressive function in vivo.
|
22692497 |
2012 |
Graft-vs-Host Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Donor- but not host-derived interleukin-10 contributes to the regulation of experimental graft-versus-host disease.
|
22262800 |
2012 |
Graft-vs-Host Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Rosiglitazone inhibited GVHD-induced increases in serum levels of tumor necrosis factor-alpha, interferon-gamma, interleukin (IL)-6, and IL-12, and the GVHD-induced decreases in transforming growth factor-beta and IL-10.
|
22982856 |
2012 |
Graft-vs-Host Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Results of a previous study with human leukocyte antigen (HLA)-identical siblings showed individual and synergistic associations of single nucleotide polymorphisms in the promoter region of the recipient's IL10 gene and the donor's IL10 receptor beta (IL-10RB) gene with development of grades III-IV acute graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation.
|
19295315 |
2009 |
Graft-vs-Host Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our results suggest that IL-10 and IL-10Rbeta genes have a synergistic effect on the risk of GvHD.
|
19409109 |
2009 |
Graft-vs-Host Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Interestingly, protection from x-GvHD after Treg administration was associated with a significant increase in plasma levels of interleukin-10 and IFN-gamma, suggesting the de novo development of TR1 cells.
|
17000688 |
2006 |
Graft-vs-Host Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The current study attempted to evaluate the association between IL-10 promoter gene polymorphism and transplant outcomes including the occurrence of chronic graft-versus-host disease (GVHD) and its clinical course during systemic immunosuppressive treatment (IST) among 60 recipients of cytokine-mobilized peripheral blood stem cell (PBSC) from HLA-matched sibling donors.
|
15940053 |
2005 |
Graft-vs-Host Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The effect of the strong IL-10 promoter allele on survival seems to be independent of the development of clinical autologous GVHD.
|
15931634 |
2005 |
Graft-vs-Host Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These data suggest an interaction of the patient IL-10/-592 and donor IL10RB/c238 genotypes on risk of GVHD, further supporting the hypothesis that the IL-10 pathway plays an important role in controlling the severity of acute GVHD.
|
16109775 |
2005 |
Graft-vs-Host Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Patients with a high anti-inflammatory IL-10 production have been demonstrated to be protected from GVHD while patients with high TNF-alpha serum levels were more at risk for GVHD.
|
15449032 |
2004 |
Graft-vs-Host Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Patients who developed moderate-to-severe acute GVHD had higher levels of TNF-alpha, IFN-gamma, IL-10 and sFas at 2 weeks post-SCT than in those with less GVHD.
|
12756021 |
2003 |
Graft-vs-Host Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation.
|
14657427 |
2003 |
Graft-vs-Host Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Analysis of cytokine gene expression in peripheral blood mononuclear cells showed that type 1 helper T cells (Th1)-derived cytokines increased in severe GVHD, while Th2-derived cytokines such as IL-4, IL-10 and IL-13 increased in mild GVHD.
|
12623423 |
2003 |
Graft-vs-Host Disease
|
0.400 |
Biomarker
|
disease |
LHGDN |
Interestingly, polymorphisms in the IL-10 promoter region may also explain differences in the susceptibility of patients to autologous GVHD induction.
|
12239181 |
2002 |
Graft-vs-Host Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Interestingly, we also found that (1) time to neutrophil recovery was shorter when donors were FcgammaRIIIb HNA-1a/HNA-1b (HR = 1.77; P =.002); (2) donor IL-1Ra (absence of IL-1RN*2) increased the risk for acute graft-versus-host disease (GVHD) (II-IV) (HR = 2.17; P =.017); and (3) recipient IL-10 (GG) and IL-1Ra genotypes increased the risk for chronic GVHD (P =.03 and P =.03, respectively).
|
12393699 |
2002 |
Graft-vs-Host Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Interestingly, polymorphisms in the IL-10 promoter region may also explain differences in the susceptibility of patients to autologous GVHD induction.
|
12239181 |
2002 |
Graft-vs-Host Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Recipients possessing longer IL-10(-1064) microsatellite alleles developed more severe acute GVHD: 22.3% of recipients possessing alleles 12 to 15 developed grade III to IV GVHD, versus 3.92% of those with smaller alleles (P <.01).
|
10572111 |
1999 |
Graft-vs-Host Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Of the 38 patients with grade 0-II GVHD, 3 of 38 had a both TNFd3/d3 and IL-10 (12-15) genotype, compared with 6 of 11 patients with grade III-IV GVHD (P <.001).
|
9808588 |
1998 |